José Baselga

José Baselga (1959-2021) was a transformative figure in breast cancer treatment who led clinical development of HER2-targeted therapies including trastuzumab, pertuzumab, and T-DM1. His clinical trials established the paradigm of dual HER2 blockade and antibody-drug conjugates in breast cancer. Baselga's legacy includes training generations of oncologists and advancing precision medicine.

José Baselga（1959-2021）是乳腺癌治疗领域的变革性人物，领导了HER2靶向治疗的临床开发，包括trastuzumab、pertuzumab和T-DM1。他的临床试验确立了乳腺癌中双重HER2阻断和抗体药物偶联物的范式。Baselga的遗产包括培训了几代肿瘤学家和推进精准医学。